We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.50 | 3.70% | 42.00 | 42.00 | 42.50 | 42.50 | 40.50 | 40.50 | 221,771 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 103.05 | 53.16M |
TIDMVLG
Venture Life Group PLC
31 January 2017
Venture Life Group plc
("Venture Life" or the "Group")
Investor Day presentation now available
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that the presentations delivered on Thursday 26 January 2017, along with the recorded audio, are now available to view on the Group's website:
http://www.venture-life.com/node/328
For further information please contact:
Hot Features
Premium
Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive
Officer
Panmure Gordon (UK) Limited (Nominated +44 (0) 20 7886
Adviser and Joint Broker) 2500
Freddy Crossley/Peter Steel/Duncan
Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Turner Pope Investments (TPI) Ltd +44 (0) 20 3621
(Joint Broker) 4120
James Pope/Ben Turner
Walbrook PR venturelife@walbrookpr.com
or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy +44 (0) 7980 541 893 / +44
(0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its Development & Manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGFMVMRGNZM
(END) Dow Jones Newswires
January 31, 2017 11:39 ET (16:39 GMT)
1 Year Venture Life Chart |
1 Month Venture Life Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
